Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 7/2013

01-07-2013 | CRYSTAL ARTHRITIS (MH PILLINGER, SECTION EDITOR)

Update on Oxalate Crystal Disease

Authors: Elizabeth C. Lorenz, Clement J. Michet, Dawn S. Milliner, John C. Lieske

Published in: Current Rheumatology Reports | Issue 7/2013

Login to get access

Abstract

Oxalate arthropathy is a rare cause of arthritis characterized by deposition of calcium oxalate crystals within synovial fluid. This condition typically occurs in patients with underlying primary or secondary hyperoxaluria. Primary hyperoxaluria constitutes a group of genetic disorders resulting in endogenous overproduction of oxalate, whereas secondary hyperoxaluria results from gastrointestinal disorders associated with fat malabsorption and increased absorption of dietary oxalate. In both conditions, oxalate crystals can deposit in the kidney leading to renal failure. Since oxalate is primarily renally eliminated, it accumulates throughout the body in renal failure, a state termed oxalosis. Affected organs can include bones, joints, heart, eyes, and skin. Since patients can present with renal failure and oxalosis before the underlying diagnosis of hyperoxaluria has been made, it is important to consider hyperoxaluria in patients who present with unexplained soft tissue crystal deposition. The best treatment of oxalosis is prevention. If patients present with advanced disease, treatment of oxalate arthritis consists of symptom management and control of the underlying disease process.
Literature
1.
2.
van Woerden CS, Groothoff JW, Wanders RJ, Davin JC, Wijburg FA. Primary hyperoxaluria type 1 in the netherlands: Prevalence and outcome. Nephrol Dial Transplant. 2003;18(2):273–9.PubMedCrossRef
3.
•• Hoppe B. An update on primary hyperoxaluria. Nat Rev Nephrol. 2012;8(8):467–75. An excellent review of primary hyperoxaluria.PubMedCrossRef
4.
Lieske JC, Monico CG, Holmes WS, Bergstralh EJ, Slezak JM, Rohlinger AL, et al. International registry for primary hyperoxaluria. Am J Nephrol. 2005;25(3):290–6.PubMedCrossRef
5.
•• Belostotsky R, Seboun E, Idelson GH, Milliner DS, Becker-Cohen R, Rinat C, et al. Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am J Hum Genet. 2010;87(3):392–9. Initial description of the genetic mutations responsible for primary hyperoxaluria type 3.PubMedCrossRef
6.
• Monico CG, Rossetti S, Belostotsky R, Cogal AG, Herges RM, Seide BM, et al. Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. Clin J Am Soc Nephrol. 2011;6(9):2289–95. A study suggesting that genetic mutations involved in primary hyperoxaluria type 3 may also be a risk factor for idiopathic kidney stones.PubMedCrossRef
7.
Riedel TJ, Knight J, Murray MS, Milliner DS, Holmes RP, Lowther WT. 4-Hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibition. Biochim Biophys Acta. 2012;1822(10):1544–52.PubMedCrossRef
8.
Cornelis T, Bammens B, Lerut E, Cosyn L, Goovaerts G, Westhovens R, et al. AA amyloidosis due to chronic oxalate arthritis and vasculitis in a patient with secondary oxalosis after jejunoileal bypass surgery. Nephrol Dial Transplant. 2008;23(10):3362–4.PubMedCrossRef
9.
Dobbins JW, Binder HJ. Importance of the colon in enteric hyperoxaluria. N Engl J Med. 1977;296(6):298–301.PubMedCrossRef
10.
•• Kumar R, Lieske JC, Collazo-Clavell ML, Sarr MG, Olson ER, Vrtiska TJ, et al. Fat malabsorption and increased intestinal oxalate absorption are common after roux-en-Y gastric bypass surgery. Surgery. 2011;149(5):654–61. A study decribing the incidence of increased oxalate absorption following bariatric surgery.PubMedCrossRef
11.
Dobbins JW, Binder HJ. Effect of bile salts and fatty acids on the colonic absorption of oxalate. Gastroenterology. 1976;70(6):1096–100.PubMed
12.
Hylander E, Jarnum S, Jensen HJ, Thale M. Enteric hyperoxaluria: Dependence on small intestinal resection, colectomy, and steatorrhoea in chronic inflammatory bowel disease. Scand J Gastroenterol. 1978;13(5):577–88.PubMedCrossRef
13.
Hueppelshaeuser R, von Unruh GE, Habbig S, Beck BB, Buderus S, Hesse A, et al. Enteric hyperoxaluria, recurrent urolithiasis, and systemic oxalosis in patients with Crohn's disease. Pediatr Nephrol. 2012;27(7):1103–9.PubMedCrossRef
14.
Ciacci C, Spagnuolo G, Tortora R, Bucci C, Franzese D, Zingone F, et al. Urinary stone disease in adults with celiac disease: Prevalence, incidence and urinary determinants. J Urol. 2008;180(3):974–9.PubMedCrossRef
15.
Cartery C, Faguer S, Karras A, Cointault O, Buscail L, Modesto A, et al. Oxalate nephropathy associated with chronic pancreatitis. Clin J Am Soc Nephrol. 2011;6(8):1895–902.PubMedCrossRef
16.
• Rahman N, Hitchcock R. Case report of paediatric oxalate urolithiasis and a review of enteric hyperoxaluria. J Pediatr Urol. 2010;6(2):112–6. A review of enteric hyperoxaluria in children.PubMedCrossRef
17.
Nasr SH, D'Agati VD, Said SM, Stokes MB, Largoza MV, Radhakrishnan J, et al. Oxalate nephropathy complicating roux-en-Y gastric bypass: An underrecognized cause of irreversible renal failure. Clin J Am Soc Nephrol. 2008;3(6):1676–83.PubMedCrossRef
18.
Sinha MK, Collazo-Clavell ML, Rule A, Milliner DS, Nelson W, Sarr MG, et al. Hyperoxaluric nephrolithiasis is a complication of roux-en-Y gastric bypass surgery. Kidney Int. 2007;72(1):100–7.PubMedCrossRef
19.
• Pang R, Linnes MP, O'Connor HM, Li X, Bergstralh E, Lieske JC. Controlled metabolic diet reduces calcium oxalate supersaturation but not oxalate excretion after bariatric surgery. Urology. 2012;80(2):250–4. A study outlining the limitations of a low-oxalate diet alone following bariatric surgery.PubMedCrossRef
20.
Penniston KL, Kaplon DM, Gould JC, Nakada SY. Gastric band placement for obesity is not associated with increased urinary risk of urolithiasis compared to bypass. J Urol. 2009;182(5):2340–6.PubMedCrossRef
21.
Duffey BG, Pedro RN, Makhlouf A, Kriedberg C, Stessman M, Hinck B, et al. Roux-en-Y gastric bypass is associated with early increased risk factors for development of calcium oxalate nephrolithiasis. J Am Coll Surg. 2008;206(3):1145–53.PubMedCrossRef
22.
Froeder L, Arasaki CH, Malheiros CA, Baxmann AC, Heilberg IP. Response to dietary oxalate after bariatric surgery. Clin J Am Soc Nephrol. 2012;7(12):2033–40.PubMedCrossRef
23.
Ehlers SM, Posalaky Z, Strate RG, Quattlebaum FW. Acute reversible renal failure following jejunoileal bypass for morbid obesity: A clinical and pathological (EM) study of a case. Surgery. 1977;82:629–34.PubMed
24.
Verani R, Nasir M, Foley R. Granulomatous interstitial nephritis after a jejunoileal bypass: An ultrastructural and histochemical study. Am J Nephrol. 1989;9(1):51–5.PubMedCrossRef
25.
Sarica K, Akarsu E, Erturhan S, Yagci F, Aktaran S, Altay B. Evaluation of urinary oxalate levels in patients receiving gastrointestinal lipase inhibitor. Obesity (Silver Spring). 2008;16(7):1579–84.CrossRef
26.
Karamadoukis L, Shivashankar GH, Ludeman L, Williams AJ. An unusual complication of treatment with orlistat. Clin Nephrol. 2009;71(4):430–2.PubMed
27.
Hatch M, Freel RW. Intestinal transport of an obdurate anion: Oxalate. Urol Res. 2005;33(1):1–16.PubMedCrossRef
28.
Hatch M, Cornelius J, Allison M, Sidhu H, Peck A, Freel RW. Oxalobacter sp. Reduces urinary oxalate excretion by promoting enteric oxalate secretion. Kidney Int. 2006;69(4):691–8.PubMedCrossRef
29.
Hatch M, Freel RW, Vaziri ND. Regulatory aspects of oxalate secretion in enteric oxalate elimination. J Am Soc Nephrol. 1999;10 Suppl 14:S324–8.PubMed
30.
Jacobsen D, Hewlett TP, Webb R, Brown ST, Ordinario AT, McMartin KE. Ethylene glycol intoxication: Evaluation of kinetics and crystalluria. Am J Med. 1988;84(1):145–52.PubMedCrossRef
31.
Brent J, McMartin K, Phillips S, Burkhart KK, Donovan JW, Wells M, et al. Fomepizole for the treatment of ethylene glycol poisoning. Methylpyrazole for toxic alcohols study group. N Engl J Med. 1999;340(11):832–8.PubMedCrossRef
32.
Sanz P, Reig R. Clinical and pathological findings in fatal plant oxalosis. A review. The American journal of forensic medicine and pathology. 1992;13(4):342–5.PubMedCrossRef
33.
34.
Lieske JC, Swift HS, Martin T, Patterson B, Toback FG. Renal epithelial cells rapidly bind and internalize calcium oxalate monohydrate crystals. ProcNatlAcadSci, USA. 1994;91:6987–91.CrossRef
35.
Lieske JC, Toback FG. Regulation of renal epithelial cell endocytosis of calcium oxalate monohydrate crystals. Am J Physiol. 1993;264:F800–F7.PubMed
36.
Hammes MS, Lieske JC, Pawar S, Spargo BH, Toback FG. Calcium oxalate monohydrate crystals stimulate gene expression in renal epithelial cells. Kidney Int. 1995;48:501–9.PubMedCrossRef
37.
Lieske JC, Walsh-Reitz MM, Toback FG. Calcium oxalate monohydrate crystals are endocytosed by renal epithelial cells and induce proliferation. AmJPhysiol. 1992;262:F622–F30.
38.
Lieske JC, Deganello S, Toback FG. Cell-crystal interactions and kidney stone formation. Nephron. 1999;81(S1):S8–S17.CrossRef
39.
Khan SR, Finlayson B, Hackett RL. Scanning electron microscopy of calcium oxalate crystal formation in experimental nephrolithiasis. LabInvest. 1979;41:504–10.
40.
Dykstra MJ, Hackett RL. Ultrastructural events in early calcium oxalate crystal formation in rats. Kidney Int. 1979;15:640–50.PubMedCrossRef
41.
Khan SR, Finlayson B, Hackett RL. Histologic study of the early events in oxalate induced intranephronic calculosis. InvestUrol. 1979;17:199–202.
42.
Lieske JC, Spargo BH, Toback FG. Endocytosis of calcium oxalate crystals and proliferation of renal tubular epithelial cells in a patient with type 1 primary hyperoxaluria. J Urol. 1992;148(5):1517–9.PubMed
43.
•• Cochat P, Hulton SA, Acquaviva C, Danpure CJ, Daudon M, De Marchi M, et al. Primary hyperoxaluria type 1: Indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant. 2012;27(5):1729–36. A review of methods used to diagnose primary hyperoxaluria.PubMedCrossRef
44.
Kohn NN, Hughes RE, Mc Jr CD, Faires JS. The significance of calcium phosphate crystals in the synovial fluid of arthritic patients: The "pseudogout syndrome". II. Identification of crystals. Ann Intern Med. 1962;56:738–45.PubMedCrossRef
45.
Sarraf P, Kay J, Reginato AM. Non-crystalline and crystalline rheumatic disorders in chronic kidney disease. Curr Rheumatol Rep. 2008;10(3):235–48.PubMedCrossRef
46.
Verbruggen LA, Bourgain C, Verbeelen D. Late presentation and microcrystalline arthropathy in primary hyperoxaluria. Clin Exp Rheumatol. 1989;7(6):631–3.PubMed
47.
Rosenthal A, Ryan LM, McCarty DJ. Arthritis associated with calcium oxalate crystals in an anephric patient treated with peritoneal dialysis. Jama. 1988;260(9):1280–2.PubMedCrossRef
48.
Maldonado I, Prasad V, Reginato AJ. Oxalate crystal deposition disease. Curr Rheumatol Rep. 2002;4(3):257–64.PubMedCrossRef
49.
•• Bacchetta J, Fargue S, Boutroy S, Basmaison O, Vilayphiou N, Plotton I, et al. Bone metabolism in oxalosis: A single-center study using new imaging techniques and biomarkers. Pediatr Nephrol. 2010;25(6):1081–9. A study of bone imaging and FGF23 levels in patients with primary hyperoxaluria.PubMedCrossRef
50.
El Hage S, Ghanem I, Baradhi A, Mourani C, Mallat S, Dagher F, et al. Skeletal features of primary hyperoxaluria type 1, revisited. J Child Orthop. 2008;2(3):205–10.PubMedCrossRef
51.
Behnke B, Kemper MJ, Kruse HP, Muller-Wiefel DE. Bone mineral density in children with primary hyperoxaluria type I. Nephrol Dial Transplant. 2001;16(11):2236–9.PubMedCrossRef
52.
53.
54.
Tapia G, Navarro JT, Navarro M. Leukoerythroblastic anemia due to oxalosis with extensive bone marrow involvement. Am J Hematol. 2008;83(6):515–6.PubMedCrossRef
55.
Mookadam F, Smith T, Jiamsripong P, Moustafa SE, Monico CG, Lieske JC, et al. Cardiac abnormalities in primary hyperoxaluria. Circ J. 2010;74(11):2403–9.PubMedCrossRef
56.
Van Driessche L, Dhondt A, De Sutter J. Heart failure with mitral valve regurgitation due to primary hyperoxaluria type 1: Case report with review of the literature. Acta Cardiol. 2007;62(2):202–6.PubMedCrossRef
57.
•• Blackmon JA, Jeffy BG, Malone JC, Knable Jr AL. Oxalosis involving the skin: Case report and literature review. Arch Dermatol. 2011;147(11):1302–5. A review of how oxalosis affects the skin.PubMedCrossRef
58.
Fielder AR, Garner A, Chambers TL. Ophthalmic manifestations of primary oxalosis. Br J Ophthalmol. 1980;64(10):782–8.PubMedCrossRef
59.
Munir WM, Sharma MC, Li T, Dealba F, Goldstein DA. Retinal oxalosis in primary hyperoxaluria type 1. Retina. 2004;24(6):974–6.PubMedCrossRef
60.
Small KW, Letson R, Scheinman J. Ocular findings in primary hyperoxaluria. Arch Ophthalmol. 1990;108(1):89–93.PubMedCrossRef
61.
Bilbao JM, Berry H, Marotta J, Ross RC. Peripheral neuropathy in oxalosis. A case report with electron microscopic observations. Can J Neurol Sci. 1976;3(1):63–7.PubMed
62.
Galloway G, Giuliani MJ, Burns DK, Lacomis D. Neuropathy associated with hyperoxaluria: Improvement after combined renal and liver transplantations. Brain Pathol. 1998;8(2):247–51.PubMedCrossRef
63.
Hall BM, Walsh JC, Horvath JS, Lytton DG. Peripheral neuropathy complicating primary hyperoxaluria. J Neurol Sci. 1976;29(2–4):343–9.PubMedCrossRef
64.
Moorhead PJ, Cooper DJ, Timperley WR. Progressive peripheral neuropathy in patient with primary hyperoxaluria. Br Med J. 1975;2(5966):312–3.PubMedCrossRef
65.
Mitsimponas KT, Wehrhan T, Falk S, Wehrhan F, Neukam FW, Schlegel KA. Oral findings associated with primary hyperoxaluria type I. J Craniomaxillofac Surg. 2012;40(8):e301–6.PubMedCrossRef
66.
Panis V, Tosios KI, Gagari E, Griffin TJ, Damoulis PD. Severe periodontitis in a patient with hyperoxaluria and oxalosis: A case report and review of the literature. J Periodontol. 2010;81(10):1497–504.PubMedCrossRef
67.
Rinksma AJ, Oosterhuis JW, Wolvius EB, van der Wal KG. Oral manifestations of oxalosis: A case report and review of the literature. J Oral Maxillofac Surg. 2008;66(9):1953–6.PubMedCrossRef
68.
Fishbein GA, Micheletti RG, Currier JS, Singer E, Fishbein MC. Atherosclerotic oxalosis in coronary arteries. Cardiovasc Pathol. 2008;17(2):117–23.PubMedCrossRef
69.
Tanriover B, Mejia A, Foster SV, Mubarak A. Primary hyperoxaluria involving the liver and hepatic artery: Images of an aggressive disease. Kidney Int. 2010;77(7):651.PubMedCrossRef
70.
Milliner DS, Eickholt JT, Bergstralh E, Wilson DM, Smith LH. Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. New Engl J Med. 1994;331:1553–8.PubMedCrossRef
71.
Mandell I, Krauss E, Millan JC. Oxalate-induced acute renal failure in Crohn's disease. AmJMed. 1980;69:628–32.
72.
Earnest DL, Johnson G, Williams HE, Admirand WH. Hyperoxaluria in patients with ileal resection: An abnormality in dietary oxalate absorption. Gastroenterology. 1974;66(6):1114–22.PubMed
73.
74.
• Mulay SR, Kulkarni OP, Rupanagudi KV, Migliorini A, Darisipudi MN, Vilaysane A, et al. Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1beta secretion. J Clin Invest. 2013;123(1):236–46. A study demonstrating how calcium oxalate crystals induce IL-1β secretion.PubMedCrossRef
75.
Rankin AC, Walsh SB, Summers SA, Owen MP, Mansell MA. Acute oxalate nephropathy causing late renal transplant dysfunction due to enteric hyperoxaluria. Am J Transplant. 2008;8(8):1755–8.PubMedCrossRef
76.
Robijn S, Vervaet BA, Hoppe B, D'Haese PC, Verhulst A. Lanthanum carbonate inhibits intestinal oxalate absorption and prevents nephrocalcinosis after oxalate loading in rats. J Urol 2012 Dec 7.
77.
Lieske JC, Regnier C, Dillon JJ. Use of sevelamer hydrochloride as an oxalate binder. J Urol. 2008;179(4):1407–10.PubMedCrossRef
78.
Lieske JC, Goldfarb DS, De Simone C, Regnier C. Use of a probiotic to decrease enteric hyperoxaluria. Kidney Int. 2005;68(3):1244–9.PubMedCrossRef
79.
•• Lieske JC, Tremaine WJ, De Simone C, O'Connor HM, Li X, Bergstralh EJ, et al. Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation. Kidney Int. 2010;78(11):1178–85. A study investigating the role of diet and priobiotics on urinary oxalate excretion in patients with hyperoxaluria.PubMedCrossRef
80.
Gibbs DA, Watts RW. The action of pyridoxine in primary hyperoxaluria. Clin Sci. 1970;38(2):277–86.PubMed
81.
Watts RW, Veall N, Purkiss P, Mansell MA, Haywood EF. The effect of pyridoxine on oxalate dynamics in three cases of primary hyperoxaluria (with glycollic aciduria). Clin Sci. 1985;69(1):87–90.PubMed
82.
• Fargue S, Lewin J, Rumsby G, Danpure CJ. Four of the most common mutations in primary hyperoxaluria type 1 unmask the cryptic mitochondrial targeting sequence of alanine:glyoxylate aminotransferase encoded by the polymorphic minor allele. J Biol Chem 2012 Dec 10. A study showing how specific mutations result in mistargeting of the the peroxisomal enzyme alanine:glyoxylate aminotransferase (AGT) to mitochondria in primary hyperoxaluria.
83.
Monico CG, Rossetti S, Olson JB, Milliner DS. Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele. Kidney Int. 2005;67(5):1704–9.PubMedCrossRef
84.
Illies F, Bonzel KE, Wingen AM, Latta K, Hoyer PF. Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1. Kidney Int. 2006;70(9):1642–8.PubMedCrossRef
85.
Franssen CF. Oxalate clearance by haemodialysis–a comparison of seven dialysers. Nephrol Dial Transplant. 2005;20(9):1916–21.PubMedCrossRef
86.
Hoppe B, Graf D, Offner G, Latta K, Byrd DJ, Michalk D, et al. Oxalate elimination via hemodialysis or peritoneal dialysis in children with chronic renal failure. Pediatr Nephrol. 1996;10(4):488–92.PubMedCrossRef
87.
Hoppe B, Langman CB. A united states survey on diagnosis, treatment, and outcome of primary hyperoxaluria. Pediatr Nephrol. 2003;18(10):986–91.PubMedCrossRef
88.
Hoppe B, Latta K, von Schnakenburg C, Kemper MJ. Primary hyperoxaluria−the german experience. Am J Nephrol. 2005;25(3):276–81.PubMedCrossRef
89.
• Cochat P, Fargue S, Harambat J. Primary hyperoxaluria type 1: Strategy for organ transplantation. Curr Opin Organ Transplant. 2010;15(5):590–3. An overview of transplant options for patients with primary hyeroxaluria.PubMedCrossRef
90.
•• Bergstralh EJ, Monico CG, Lieske JC, Herges RM, Langman CB, Hoppe B, et al. Transplantation outcomes in primary hyperoxaluria. Am J Transplant. 2010;10(11):2493–501. A study examining the outcome of transplantation in patients with primary hyperoxaluria over the past decade.PubMedCrossRef
91.
Monico CG, Milliner DS. Combined liver-kidney and kidney-alone transplantation in primary hyperoxaluria. Liver Transpl. 2001;7(11):954–63.PubMedCrossRef
92.
Allison MJ, Dawson KA, Mayberry WR, Foss JG. Oxalobacter formigenes gen. nov., sp. nov.: oxalate-degrading anaerobes that inhabit the gastrointestinal tract. Arch Microbiol. 1985;141(1):1–7.PubMedCrossRef
93.
Grujic D, Salido EC, Shenoy BC, Langman CB, McGrath ME, Patel RJ, et al. Hyperoxaluria is reduced and nephrocalcinosis prevented with an oxalate-degrading enzyme in mice with hyperoxaluria. Am J Nephrol. 2009;29(2):86–93.PubMedCrossRef
94.
•• Hatch M, Gjymishka A, Salido EC, Allison MJ, Freel RW. Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization with oxalobacter. Am J Physiol Gastrointest Liver Physiol. 2011;300(3):G461–9. Examination of the beneficial effect of Oxalobacter in mice with primary hyperoxaluria.PubMedCrossRef
95.
Sidhu H, Schmidt ME, Cornelius JG, Thamilselvan S, Khan SR, Hesse A, et al. Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium oxalobacter formigenes: Possible prevention by gut recolonization or enzyme replacement therapy. J Am Soc Nephrol. 1999;10 Suppl 14:S334–40.PubMed
96.
Hatch M, Freel RW. Renal and intestinal handling of oxalate following oxalate loading in rats. Am J Nephrol. 2003;23(1):18–26.PubMedCrossRef
97.
Hoppe B, Beck B, Gatter N, von Unruh G, Tischer A, Hesse A, et al. Oxalobacter formigenes: A potential tool for the treatment of primary hyperoxaluria type 1. Kidney Int. 2006;70(7):1305–11.PubMedCrossRef
98.
•• Hoppe B, Groothoff JW, Hulton SA, Cochat P, Niaudet P, Kemper MJ, et al. Efficacy and safety of oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria. Nephrology, dialysis, transplantation : Official publication of the european dialysis and transplant association. European Renal Association. 2011;26(11):3609–15. Lack of effect of Oxalobacter on urinary oxalate excretion in patients with primary hyperoxaluria.
99.
• Salido E, Rodriguez-Pena M, Santana A, Beattie SG, Petry H, Torres A. Phenotypic correction of a mouse model for primary hyperoxaluria with adeno-associated virus gene transfer. Mol Ther. 2011;19(5):870–5. A study describing the successful treatment of hyperoxaluria in mice using gene transfer.PubMedCrossRef
100.
Hopper ED, Pittman AM, Fitzgerald MC, Tucker CL. In vivo and in vitro examination of stability of primary hyperoxaluria-associated human alanine:Glyoxylate aminotransferase. J Biol Chem. 2008;283(45):30493–502.PubMedCrossRef
101.
Lumb MJ, Birdsey GM, Danpure CJ. Correction of an enzyme trafficking defect in hereditary kidney stone disease in vitro. Biochem J. 2003;374(Pt 1):79–87.PubMedCrossRef
Metadata
Title
Update on Oxalate Crystal Disease
Authors
Elizabeth C. Lorenz
Clement J. Michet
Dawn S. Milliner
John C. Lieske
Publication date
01-07-2013
Publisher
Springer US
Published in
Current Rheumatology Reports / Issue 7/2013
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-013-0340-4

Other articles of this Issue 7/2013

Current Rheumatology Reports 7/2013 Go to the issue

PEDIATRIC RHEUMATOLOGY (TJA LEHMAN, SECTION EDITOR)

Current Perspectives on Ophthalmic Manifestations of Childhood Rheumatic Diseases

PEDIATRIC RHEUMATOLOGY (TJA LEHMAN, SECTION EDITOR)

Tocilizumab in Pediatric Rheumatology: The Clinical Experience

SYSTEMIC LUPUS ERYTHEMATOSUS (M PETRI, SECTION EDITOR)

Ten Developments in the Use of Biologicals for Systemic Lupus Erythematosus

ANTIPHOSPHOLIPID SYNDROME (RAS ROUBEY, SECTION EDITOR)

Clinical Significance of IgA Anti-Cardiolipin and IgA Anti-β2Glycoprotein I Antibodies

SERONEGATIVE ARTHRITIS (MA KHAN, SECTION EDITOR)

Osteoimmunology and Bone Homeostasis: Relevance to Spondyloarthritis

COMPLEMENTARY AND ALTERNATIVE MEDICINE (SL KOLASINSKI, SECTION EDITOR)

Manipulative Therapy (Feldenkrais, Massage, Chiropractic Manipulation) for Neck Pain
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits